FDA Grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women.
This is pretty interesting. So Pfizer's got this now, along with a soon to be approved vaccine for RSV and what looks like most of the market for the annual COVID-19 vaccine. The also acquired a therapeutics company, ReViral, for the treatment of RSV, putting them in position to have all the solutions for RSV as they have for COVID.
Assuming they settle the dispute with Moderna over IP claims within the next X years, they could emerge as the leader in vaccines. I know many have worried about its ability to continue generating the insane amount of money it has raked in from COVID vaccines, and it looks like those concerns are being answered.
I suspect given its huge cash position ($33B end of Q2), it will continue shopping for cool new therapies to add to its pipeline. Other than AstraZeneca, I don't see a pipeline this big. They just acquired a small cap company with a treatment for sickle cell disorder and I suspect others will follow.
My plan was wait until they announce a big acquisition and buy the stock on the dip, but it's getting harder to wait and they seem driven to acquire multiple small caps instead of doing something large.
Given the recent news of the lawsuit by Moderna and the September sentiment, the stock is looking attractive for a long term bet if you assume they will reach a deal with Moderna or drag it out in court for years.
Leave a Reply